Skip to content

Impax extended-release generic Concerta OKd by FDA

July 17, 2017
The Food and Drug Administration has approved Impax Laboratories’ generic of Concerta (methylphenidate hydrochloride) extended-release tablets. The drug is indicated too treat attention deficit hyperactivity disorder in patients older than 6 years of age.
“Approval of our AB-rated generic version of Concerta further demonstrates the capabilities of Impax’s R&D organization,” Impax president and CEO Paul Bisaro said. “We are preparing for launch including working to secure API quota and currently expect to launch by the end of this year. As a result, we don’t anticipate sales of generic Concerta to meaningfully impact our earnings in 2017.”
Impax’s generic will be available in 18-, 27-, 36- and 54-mg dosage strengths. The drug had U.S. sales of approximately $1.8 billion for the 12 months ended May 2017, according to QuintilesIMS data.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: